OncoMatch/Clinical Trials/NCT06550141
Emapalumab Prevention of CAR-T Cell Associated Toxicities
Official title: A Phase 2 Trial of Emapalumab for the Prevention of CAR-T Cell Associated Toxicities
Is NCT06550141 recruiting? Yes, currently enrolling (Oct 2026). This Phase 2 trial studies multiple treatments for large b-cell lymphoma.
Treatment: Emapalumab · Cyclophosphamide · Fludarabine Phosphate · Axicabtagene Ciloleucel · Dexamethasone · Lisocabtagene maraleucel — This research study involves assessing the impact of emapalumab as preventative management of CAR-T related cytokine release syndrome in participants with Non-Hodgkin's lymphoma (NHL). The research study involves the following study interventions: * Fludarabine and cyclophosphamide (Lymphodepleting Chemotherapy) * Axicabtagene Ciloleucel or Lisocabtagene Maraleucel * Emapalumab
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Chemotherapy
Other
Cancer type
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: chemoimmunotherapy — first-line
large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy
Must have received: systemic therapy
relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy
Cannot have received: allogeneic stem cell transplant
History of allogeneic stem cell transplantation.
Lab requirements
Blood counts
ANC ≥1000/uL; Platelet count ≥50,000/uL; Absolute lymphocyte count ≥100/uL
Kidney function
Creatinine clearance (as estimated by Cockcroft Gault or CKD-EPI) ≥ 30 mL/min
Liver function
Serum ALT/AST ≤2.5 per institutional ULN; Total bilirubin ≤1.5 mg/dl, except in subjects with Gilbert's syndrome.
Cardiac function
Cardiac ejection fraction ≥ 40%, no clinically significant pericardial effusion, and no clinically significant ECG findings
Adequate renal, hepatic, pulmonary and cardiac function defined as: ANC ≥1000/uL; Platelet count ≥50,000/uL; Absolute lymphocyte count ≥100/uL; Creatinine clearance (as estimated by Cockcroft Gault or CKD-EPI) ≥ 30 mL/min; Serum ALT/AST ≤2.5 per institutional ULN; Total bilirubin ≤1.5 mg/dl, except in subjects with Gilbert's syndrome; Cardiac ejection fraction ≥ 40%, no clinically significant pericardial effusion, and no clinically significant ECG findings; Baseline oxygen saturation >92% on room air.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Massachusetts General Hospital · Boston, Massachusetts
- Dana-Farber Cancer Institute · Boston, Massachusetts
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06550141 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior allogeneic stem cell transplant disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify